The Treatment of Meningococcic Meningitis With Sulfanilamide

Schwentker, Francis F.

doi:10.1001/jama.1937.02780170025009

Cited by 80 publications

(12 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The meningococcus was recognized as a habitant of the nasopharynx of healthy individuals (5), especially seen in the setting of military recruits camps (6) at the beginning of the twentieth century. Treatment for meningococcal disease included serum therapy introduced in 1913 by Flexner (7) and sulfonamides introduced in 1937 (8). The emergence of resistance to sulfonamides (9) in the 1960s prompted the development of the first vaccines against meningococci (10).…”

Section: Introductionmentioning

confidence: 99%

Neisseria meningitidis: Biology, Microbiology, and Epidemiology

Rouphael

Stephens

2011

Methods in Molecular Biology

332

294

View full text Add to dashboard Cite

Neisseria meningitidis (the meningococcus) causes significant morbidity and mortality in children and young adults worldwide through epidemic or sporadic meningitis and/or septicemia. In this review, we describe the biology, microbiology, and epidemiology of this exclusive human pathogen. N. meningitidis is a fastidious, encapsulated, aerobic gram-negative diplococcus. Colonies are positive by the oxidase test and most strains utilize maltose. The phenotypic classification of meningococci, based on structural differences in capsular polysaccharide, lipooligosaccharide (LOS) and outer membrane proteins, is now complemented by genome sequence typing (ST). The epidemiological profile of N. meningitidis is variable in different populations and over time and virulence of the meningococcus is based on a transformable/plastic genome and expression of certain capsular polysaccharides (serogroups A, B, C, W-135, Y and X) and non-capsular antigens. N. meningitidis colonizes mucosal surfaces using a multifactorial process involving pili, twitching motility, LOS, opacity associated, and other surface proteins. Certain clonal groups have an increased capacity to gain access to the blood, evade innate immune responses, multiply, and cause systemic disease. Although new vaccines hold great promise, meningococcal infection continues to be reported in both developed and developing countries, where universal vaccine coverage is absent and antibiotic resistance increasingly more common.

show abstract

Section: Introductionmentioning

confidence: 99%

Neisseria meningitidis: Biology, Microbiology, and Epidemiology

Rouphael

Stephens

2011

Methods in Molecular Biology

332

294

View full text Add to dashboard Cite

show abstract

“…As a consequence, sulfa nephropathy has become increasingly common . Sulfanilamides are used also to treat meningococcal meningitis . Halogenated sulfonamide derivatives have the potential for developing antimycobacterial agents against many strains exhibiting multidrug resistance …”

mentioning

confidence: 99%

Effect of sulfa drugs on kidney function and renal scintigraphy

Mustafa¹,

Alsughayer

Elgazzar

et al. 2014

Nephrology

View full text Add to dashboard Cite

show abstract

“…Thus the conjugated sulfanilamide on the three dates was 23, 16 and 46 per cent, respectively. The antistreptolysin concentration in the blood serum, which was 1,600 units on admission, dropped to 1,000 and then went to 1,200 units, where it remained for over two months.…”

Section: Methodsmentioning

confidence: 84%

The Action of Sulfanilamide in Rheumatic Fever

Swift¹

1938

JAMA

View full text Add to dashboard Cite

The Treatment of Meningococcic Meningitis With Sulfanilamide

Cited by 80 publications

References 1 publication

Neisseria meningitidis: Biology, Microbiology, and Epidemiology

Neisseria meningitidis: Biology, Microbiology, and Epidemiology

Effect of sulfa drugs on kidney function and renal scintigraphy

The Action of Sulfanilamide in Rheumatic Fever

Contact Info

Product

Resources

About